UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

Science (American Association for the Advancement of Science), 2004-07, Vol.305 (5683), p.528-532

2004

Volltextzugriff (PDF)

HIV-1 Integrase: Mechanism and Inhibitor Design

1. Aufl., 2011

Volltextzugriff (PDF)

New scaffolds of natural origin as Integrase–LEDGF/p75 interaction inhibitors: Virtual screening and activity assays

European journal of medicinal chemistry, 2013-10, Vol.68, p.405-411

2013

Volltextzugriff (PDF)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

Antimicrobial agents and chemotherapy, 2016-12, Vol.60 (12), p.7086-7097

2016

Volltextzugriff (PDF)

The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes

Clinical infectious diseases, 2020-12, Vol.71 (10), p.e549-e560

2020

Volltextzugriff (PDF)

Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia

Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8189-8206

2016

Volltextzugriff (PDF)

Synthesis and antiviral properties of some polyphenols related to Salvia genus

Bioorganic & medicinal chemistry, 2008-08, Vol.18 (16), p.4736-4740

2008

Volltextzugriff (PDF)

Inhibitors of Strand Transfer That Prevent Integration and Inhibit Human T-Cell Leukemia Virus Type 1 Early Replication

Antimicrobial Agents and Chemotherapy, 2008-10, Vol.52 (10), p.3532-3541

2008

Volltextzugriff (PDF)

Structural basis of second-generation HIV integrase inhibitor action and viral resistance

Science (American Association for the Advancement of Science), 2020-02, Vol.367 (6479), p.806-810

2020

Volltextzugriff (PDF)

In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

Antimicrobial Agents and Chemotherapy, 2011-02, Vol.55 (2), p.813-821

2011

Volltextzugriff (PDF)

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance

Journal of antimicrobial chemotherapy, 2020-01, Vol.75 (1), p.170-182

2020

Volltextzugriff (PDF)

Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)

Molecular pharmacology, 2011-10, Vol.80 (4), p.565-572

2011

Volltextzugriff (PDF)

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0138622-e0138622

2023

Volltextzugriff (PDF)

HIV-1 antiretroviral drug therapy

Cold Spring Harbor perspectives in medicine, 2012-04, Vol.2 (4), p.a007161-a007161

2012

Volltextzugriff (PDF)

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

Antimicrobial Agents and Chemotherapy, 2011-10, Vol.55 (10), p.4552-4559

2011

Volltextzugriff (PDF)

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

Journal of medicinal chemistry, 2008-09, Vol.51 (18), p.5843-5855

2008

Volltextzugriff (PDF)

Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase

Antimicrobial agents and chemotherapy, 2023-07, Vol.67 (7), p.e0046223-e0046223

2023

Volltextzugriff (PDF)

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance

Proceedings of the National Academy of Sciences - PNAS, 2010-11, Vol.107 (46), p.20057-20062

2010

Volltextzugriff (PDF)

Advances in the development of HIV integrase strand transfer inhibitors

European journal of medicinal chemistry, 2021-12, Vol.225, p.113787-113787, Article 113787

2021

Volltextzugriff (PDF)

Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

Antimicrobial agents and chemotherapy, 2014-06, Vol.58 (6), p.3233-3244

2014

Volltextzugriff (PDF)

Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition

The Journal of biological chemistry, 2019-10, Vol.294 (41), p.15137-15157

Engelman, Alan N.

2019

Volltextzugriff (PDF)

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults

Journal of acquired immune deficiency syndromes (1999), 2017-05, Vol.75 (1), p.61-66

2017

Volltextzugriff (PDF)

Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization

Antimicrobial Agents and Chemotherapy, 2012-08, Vol.56 (8), p.4365-4374

2012

Volltextzugriff (PDF)

Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe

Clinical infectious diseases, 2023-05, Vol.76 (9), p.1628-1635

2023

Volltextzugriff (PDF)

Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602

Journal of virology, 2022-03, Vol.96 (6), p.e0184321-e0184321

2022

Volltextzugriff (PDF)

1 – 25 von 2.174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.060)
Mit Volltextzugriff
(1.774)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.981)
Life Sciences & Biomedicine
(1.868)
Humans
(1.569)
Pharmacology & Pharmacy
(1.195)
Hiv Integrase Inhibitors - Pharmacology
(1.141)
Hiv Infections - Drug Therapy
(750)
Hiv-1 - Drug Effects
(726)
Hiv
(640)
Human Immunodeficiency Virus
(625)
Biological And Medical Sciences
(588)
Hiv Integrase Inhibitors - Chemistry
(574)
Antiviral Agents
(556)
Medical Sciences
(548)
Integrase
(543)
Hiv Integrase - Metabolism
(539)
Chemistry, Medicinal
(530)
Infectious Diseases
(506)
Human Immunodeficiency Virus 1
(499)
Pharmacology. Drug Treatments
(497)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(436)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

HIV-1 Integrase: Mechanism and Inhibitor Design

New scaffolds of natural origin as Integrase–LEDGF/p75 interaction inhibitors: Virtual screening and activity assays

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes

Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia

Synthesis and antiviral properties of some polyphenols related to Salvia genus

Inhibitors of Strand Transfer That Prevent Integration and Inhibit Human T-Cell Leukemia Virus Type 1 Early Replication

Structural basis of second-generation HIV integrase inhibitor action and viral resistance

In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance

Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

HIV-1 antiretroviral drug therapy

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance

Advances in the development of HIV integrase strand transfer inhibitors

Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults

Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization

Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe

Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602

Suchergebnisse filtern